Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:14 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Inhaled Prostaglandin E1 (IPGE1) for Hypoxemic Respiratory Failure (NHRF)
NCT01467076 · NICHD Neonatal Research Network · PHASE2 · terminated · last registry update 2019-04-24 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was halted due to futility concerns based on the unmet benchmarks as specified in the pilot study protocol.” | – | Registry record, NICHD Neonatal Research Network |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PTGER1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-04-10Phase 3 first posted: Cairo University, vaginal dinoprostone + Lidocaine-prilocaine Cream (NCT04340778)
- 2020-03-10Phase 3 first posted: Cairo University, vaginal dinoprostone + vaginal misoprostol (NCT04301349)
- 2020-03-09Results posted on the registry: Sucampo Pharma Americas, LLC, Cohort 1: Lubiprostone Capsule, Fasted + Cohort 1: Lubiprostone Sprinkle Formulation, Fasted (NCT03010631)
- 2020-02-06Results posted on the registry: Pediatrix, CERVIDIL (Dinoprostone) (NCT01402050)
- 2020-01-21Results posted on the registry: Sucampo Pharma Americas, LLC, Lubiprostone (NCT02138136)
- 2020-01-14Results posted on the registry: Sucampo Pharma Americas, LLC, Lubiprostone + Placebo (NCT03097861)
- 2019-12-30Results posted on the registry: Sucampo Pharma Americas, LLC, Lubiprostone 24 (NCT00620061)
- 2019-12-27Results posted on the registry: Sucampo Pharma Americas, LLC, Lubiprostone + Placebo (NCT02544152)
- 2019-12-27Also stopped (terminated): Sucampo Pharma Americas, LLC, Lubiprostone + Placebo (NCT02544152)
- 2019-12-24Results posted on the registry: Sucampo Pharma Americas, LLC, Lubiprostone + Placebo (NCT01298219)
- 2019-12-13Results posted on the registry: Mallinckrodt, Lubiprostone + Placebo (NCT01993875)
- 2019-12-06Results posted on the registry: Spaulding Rehabilitation Hospital, a drug against PTGER1 (NCT02615535)
- 2019-09-11Phase 3 first posted: Cairo University, long interval dinoprostone + short interval dinoprostone (NCT04085757)
- 2019-09-06Phase 3 first posted: Cairo University, Dinoprostone 3 mg + placebo (NCT04080323)
- 2019-09-06Phase 3 first posted: Cairo University, Dinoprostone 3 mg + placebo (NCT04080375)
- 2019-06-20Results posted on the registry: Mayo Clinic, Misoprostol (NCT02546193)
- 2019-06-20Also stopped (terminated): Mayo Clinic, Misoprostol (NCT02546193)
- 2019-05-03Results posted on the registry: University of Oklahoma, Cervidil 10 MG Vaginal Insert (NCT03111316)
- 2019-04-29Phase 3 first posted: Zagazig University, Misoprostol + Vasopressin (NCT03930069)
- 2019-04-01Results posted on the registry: Takeda, Lubiprostone + Placebo (NCT02729909)
- 2019-03-22Also stopped (withdrawn): NICHD Neonatal Research Network, Inhaled Prostaglandin E1 (NCT00598429)
- 2019-01-16Phase 3 first posted: Intermountain Health Care, Inc., Outpatient Dinoprostone 10mg + Inpatient Dinoprostone 10 mg (NCT03806231)
- 2019-01-15Results posted on the registry: Augusta University, Lubiprostone + Lubiprostone Control (NCT01190020)
- 2019-01-02Results posted on the registry: City of Hope Medical Center, sildenafil citrate + alprostadil (NCT00544076)
- 2019-01-02Also stopped (terminated): City of Hope Medical Center, sildenafil citrate + alprostadil (NCT00544076)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision